Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-EB-PSMA-617 in mCRPC
NCT03780075Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 177Lu-EB-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Change of the Prostate-Specific Antigen at 1 year and Change of standardized uptake value of 68Ga-PSMA at 1 year. Status: unknown.
02
Drugs
177Lu-EB-PSMA-617
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03780075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780075.